Display options
Cite
Granata V, Fusco R, Avallone A, et al. Critical analysis of the major and ancillary imaging features of LI-RADS on 127 proven HCCs evaluated with functional and morphological MRI: Lights and shadows. Oncotarget. 2017;8(31):51224-51237doi: 10.18632/oncotarget.17227.
Granata, V., Fusco, R., Avallone, A., Filice, F., Tatangelo, F., Piccirillo, M., Grassi, R., Izzo, F., & Petrillo, A. (2017). Critical analysis of the major and ancillary imaging features of LI-RADS on 127 proven HCCs evaluated with functional and morphological MRI: Lights and shadows. Oncotarget, 8(31), 51224-51237. https://doi.org/10.18632/oncotarget.17227
Granata, Vincenza, et al. "Critical analysis of the major and ancillary imaging features of LI-RADS on 127 proven HCCs evaluated with functional and morphological MRI: Lights and shadows." Oncotarget vol. 8,31 (2017): 51224-51237. doi: https://doi.org/10.18632/oncotarget.17227
Granata V, Fusco R, Avallone A, Filice F, Tatangelo F, Piccirillo M, Grassi R, Izzo F, Petrillo A. Critical analysis of the major and ancillary imaging features of LI-RADS on 127 proven HCCs evaluated with functional and morphological MRI: Lights and shadows. Oncotarget. 2017 Apr 19;8(31):51224-51237. doi: 10.18632/oncotarget.17227. eCollection 2017 Aug 01. PMID: 28881643; PMCID: PMC5584244.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2017 Apr 19;8(31):51224-51237. doi: 10.18632/oncotarget.17227. eCollection 2017 Aug 01.

Critical analysis of the major and ancillary imaging features of LI-RADS on 127 proven HCCs evaluated with functional and morphological MRI: Lights and shadows.

Oncotarget

Vincenza Granata, Roberta Fusco, Antonio Avallone, Francesco Filice, Fabiana Tatangelo, Mauro Piccirillo, Roberto Grassi, Francesco Izzo, Antonella Petrillo

Affiliations

  1. Department of Radiology, "Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale", Naples, Italy.
  2. Department of Abdominal Oncology, "Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale", Naples, Italy.
  3. Department of Diagnostic Pathology, "Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale", Naples, Italy.
  4. Department of Abdominal Surgical Oncology, Hepatobiliary Unit, "Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale", Naples, Italy.
  5. Department of Radiology, Second University of Naples, Piazza Miraglia, Naples, Italy.

PMID: 28881643 PMCID: PMC5584244 DOI: 10.18632/oncotarget.17227

Abstract

PURPOSE: To report a critical analysis of major and ancillary MR imaging features in assessment of HCC.

METHODS: Retrospectively we evaluated 70 cirrhotic patients with 173 nodules, which were subjected to MR study at 0 time (MR0), after 3 (MR3) and 6 months (MR6) using two different contrast media. EOB-GD-DTPA was injected at MR0 and MR6, while Gd-BT-DO3A at MR3. Three expert hepatic radiologists reviewed all images, recording, according to LI-RADS, the size, the presence and quality of arterial-phase hyperenhancement, washout and capsule appearance, threshold growth. Additionally, we recorded signal intensity (SI) on T2-W images, on DWI, on apparent diffusion coefficient (ADC) maps and SI on T1-W images of EOB-GD-BPTA hepatospecific phase. Median value of ADC and of Intravoxel incoherent motion related parameters were assessed.

RESULTS: 127 HCCs and 24 dysplastic nodules were assessed. Hypervascular on arterial phase was found in 84 HCCs, washout appearance in 124, capsule appearance in 111, hypointensity on hepatospecific phase in 127, hyperintensity on T2-W sequences and restricted diffusion in 107. Hyper vascular on arterial phase was found in 17 dysplastic nodules, wash-out appearance in 2, hypointensity on hepatospecific phase in 7 while no dysplastic nodules showed capsule appearance, hyperintensity on T2-W and restricted diffusion. Highest accuracy was obtained by washout appearance and hypointense signal on hepatospecific phase (97% and 95%).

CONCLUSIONS: Hypointensity on hepatospecific phase and washout appearance are the most relevant diagnostic sign for differentiating low-risk from high-risk HCC nodules. The capsule appearance, T2-W hyperintensity and restricted diffusion have high positive predictive value.

Keywords: HCC; Li-RADS; diffusion weighted imaging; dynamic contrast assessment; magnetic resonance imaging

Conflict of interest statement

CONFLICTS OF INTEREST The authors do not have any conflicts of interest.

References

  1. J Comput Assist Tomogr. 2010 Jul;34(4):506-12 - PubMed
  2. Radiol Med. 2016 Feb;121(2):122-31 - PubMed
  3. Hepatology. 2011 Mar;53(3):1020-2 - PubMed
  4. Clin Mol Hepatol. 2016 Jun;22(2):296-307 - PubMed
  5. Hepatology. 2008 Jan;47(1):97-104 - PubMed
  6. Eur Radiol. 2011 Jun;21(6):1233-42 - PubMed
  7. J Vasc Interv Radiol. 2015 Jul;26(7):972-9 - PubMed
  8. Biomed Res Int. 2016;2016:3918292 - PubMed
  9. Acta Radiol. 2016 Aug;57(8):932-8 - PubMed
  10. Radiology. 1988 Aug;168(2):497-505 - PubMed
  11. Abdom Imaging. 2015 Mar;40(3):613-25 - PubMed
  12. Radiology. 2006 Oct;241(1):156-66 - PubMed
  13. Abdom Imaging. 2011 Jun;36(3):232-43 - PubMed
  14. J Hepatol. 2011 Jul;55(1):126-32 - PubMed
  15. PLoS One. 2016 Dec 9;11(12 ):e0167701 - PubMed
  16. Semin Liver Dis. 2010 Feb;30(1):52-60 - PubMed
  17. Eur J Cancer. 2012 Mar;48(5):599-641 - PubMed
  18. AJR Am J Roentgenol. 2015 May;204(5):1000-7 - PubMed
  19. Eur Radiol. 2010 Oct;20(10):2405-13 - PubMed
  20. Radiology. 2011 Jun;259(3):730-8 - PubMed
  21. Radiology. 2010 May;255(2):459-66 - PubMed
  22. Invest Radiol. 2008 Mar;43(3):202-10 - PubMed
  23. Clin Liver Dis. 2015 May;19(2):325-40 - PubMed
  24. Abdom Radiol (NY). 2016 Aug;41(8):1546-54 - PubMed
  25. Eur J Radiol. 2017 Jan;86:33-40 - PubMed
  26. Infect Agent Cancer. 2014 Nov 24;9(1):39 - PubMed
  27. Adv Anat Pathol. 2015 Sep;22(5):314-22 - PubMed
  28. Ann Surg Oncol. 2012 Apr;19(4):1302-9 - PubMed
  29. Dig Dis. 2014;32(6):696-704 - PubMed
  30. AJR Am J Roentgenol. 1998 Apr;170(4):1005-13 - PubMed
  31. Radiology. 1986 Nov;161(2):401-7 - PubMed
  32. Hepatol Int. 2015 Jan;9(1):84-92 - PubMed
  33. Radiology. 2007 Sep;244(3):898-906 - PubMed
  34. AJR Am J Roentgenol. 2009 Aug;193(2):438-44 - PubMed
  35. J Magn Reson Imaging. 2012 Sep;36(3):648-57 - PubMed
  36. Eur Radiol. 2002 Apr;12(4):753-64 - PubMed
  37. Radiology. 2005 Dec;237(3):938-44 - PubMed
  38. J Radiol. 2011 Jul-Aug;92(7-8):688-700 - PubMed
  39. AJR Am J Roentgenol. 2017 Mar;208(3):544-551 - PubMed
  40. AJR Am J Roentgenol. 2011 Nov;197(5):W868-75 - PubMed
  41. Radiology. 2008 May;247(2):311-30 - PubMed
  42. Gastroenterol Res Pract. 2013;2013:469097 - PubMed
  43. Infect Agent Cancer. 2015 Apr 10;10:11 - PubMed
  44. Magn Reson Imaging Clin N Am. 2007 Aug;15(3):321-47, vi - PubMed
  45. Magn Reson Imaging Clin N Am. 2014 Aug;22(3):337-52 - PubMed
  46. Oncotarget. 2016 Nov 29;7(48):79357-79364 - PubMed
  47. J Clin Exp Hepatol. 2016 Dec;6(4):303-310 - PubMed
  48. Clin Imaging. 2017 May - Jun;43:9-14 - PubMed

Publication Types